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ficult to predict because of the variable course of the
disease in the individual patient. Data obtained in other
groups of lung transplantation candidates are not
applicable to CF because of the many peculiarities of
this disease. Consequently, the current strategy, based
on the decline of pulmonary function test results and
oxygenation, deterioration of quality of life, and
L ung transplantation is considered a viable therapeu-tic option for patients with cystic fibrosis (CF).1,2
Timing of referral is crucial to improve results and min-
imize mortality on the waiting list. Potential candidates
should be selected according to rigid criteria and only
those most likely to benefit from surgery should be
accepted; however, prognosis in CF has often been dif-
Objective: Lung transplantation is a viable option for patients with cystic
fibrosis. The current strategy of selection, based on spirometry and deterio-
ration of quality of life, results in a high mortality on the waiting list. We
reviewed the case histories of patients with cystic fibrosis accepted for lung
transplantation to ascertain whether pulmonary hemodynamics could con-
tribute to predict life expectancy. 
Methods: Forty-five patients with cystic fibrosis were accepted: 11 died on
the waiting list (group I), 24 underwent transplantation (group II), and 10 are
still waiting (group III). During evaluation we recorded spirometry, oxygen
requirement, ratio of arterial oxygen tension to inspired oxygen fraction
(PaO2/FIO2), arterial carbon dioxide tension (PaCO2), 6-minute walk test
results, right ventricular ejection fraction, echocardiography, and pulmonary
hemodynamics. We compared data from group I, II, and III patients. A com-
parison was also made within group II between the data collected at the time
of evaluation and at the time of transplantation to quantify the deterioration
during the waiting time. 
Results: The waiting time, spirometry, 6-minute walk test results, and right
ventricular ejection fraction did not differ among the three groups. A sta-
tistically significant difference was found for PaO2/FIO2, PaCO2, mean pul-
monary artery pressure, cardiac index, pulmonary arterial wedge pressure,
and intrapulmonary shunt between groups I and II. Groups I and III
showed statistically significant differences for mean pulmonary artery
pressure, PaO2/FIO2, and systemic vascular resistance indexed. No differ-
ences were observed between groups II and III. The comparison within
group II showed a significant deterioration of pulmonary hemodynamics
during the waiting time. 
Conclusions: Pulmonary hemodynamics are worst in patients dying on the
waiting list and deteriorate significantly during the waiting time. They may
thus contribute to establish priority for lung transplantation in patients with
cystic fibrosis. (J Thorac Cardiovasc Surg 2000;119:682-9)
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increased frequency of hospitalization, is often impre-
cise; as a result, mortality on the waiting list is sill high
(around 20%).3-6 Pulmonary transplantation requires
rationing of the donor resources because of the large
discrepancy between donor and recipient numbers, and
little aid can be expected by temporary mechanical
supports. In the United States, lung allocation is admin-
istered by the United Network for Organ Sharing
(UNOS) and determined by the recipient waiting time
within the region where the donor is located. This pol-
icy favors patients who can survive longer on the wait-
ing list.7,8 In Italy, like other European countries,9 a
good deal of local autonomy is allowed in favor of
patients with the worst clinical setting and the most
advanced pulmonary dysfunction; however, this may
not be the best way to determine where in the waiting
list each patient might be placed.
For all the aforementioned reasons, additional para-
meters should be evaluated to indicate at which point of
the “transplant window”10 each patient should be locat-
ed once on the waiting list and thus contribute to give
him or her priority for lung transplantation.
We reviewed our experience with lung transplanta-
tion for the treatment of CF to evaluate the possibility
that assessment of pulmonary hemodynamics could
improve referral patterns and the determination of pri-
ority among potential recipients.
Patients and methods
Between October 1996 and January 1999, 45 consecutive
patients with CF were accepted in our lung transplantation
program; this is the total group of CF patients entered on our
waiting list during the study period. There were 30 female
and 15 male patients (aged 7-38 years, mean 22 ± 5 years).
Preoperative evaluation and selection were performed
according to standard criteria. The general criteria for inclu-
sion in the waiting list for lung transplant candidates were as
follows:
• Life expectancy less than 18 to 24 months
• No significant renal or hepatic disease
• No evidence of malignancy for more than 5 years
• Ambulatory
• Able to participate in the rehabilitation program
• Psychosocial stability 
• Previous pleural procedures acceptable
The guidelines for timing referral for patients with CF were
as follows:
• Postbronchodilator forced expiratory volume in 1 second
(FEV1) less than 30% of predicted
• Resting hypoxia (PaO2 less than 55 mm Hg)
• Hypercapnia
• Increased frequency and severity of exacerbations
• Increased frequency and duration of hospitalizations
• Progressive and uncontrolled weight loss
Twenty-four (53%) patients underwent transplantation, 11
(24%) died on the waiting list, and 10 (23%) are still waiting.
At the time of evaluation, pulmonary function tests (PFT4
COSMED; Padova, Italy) were done according to the
American Thoracic Society standards; we also recorded body
weight (percent of predicted), Schwachman score, supple-
mental oxygen requirement, ratio of arterial oxygen tension
to inspired oxygen fraction (PaO2/FIO2), arterial carbon diox-
ide tension (PaCO2), 6-minute walk test results, and right ven-
tricular ejection fraction. Transthoracic 2-dimensional and
M-mode echocardiography (Hewlett-Packard 2500, Andover,
Mass) have been performed for the examination of right ven-
tricular morphology with a phased-array imaging system
with a 2.5MHz transducer. Right ventricular morphology was
classified in 4 groups: (A) normal; (B) hypertrophy without
dilatation; (C) dilatation without hypertrophy; and (D) hyper-
trophy and dilatation. The right ventricular area was calculat-
ed by planimetry from the apical 4-chamber view at end-dias-
tole,11 and it was considered to be enlarged if the right
ventricular area was more than 20.4 cm2. Right ventricular
wall hypertrophy was considered to be present when the right
ventricular wall thickness was more than 0.5 cm.11 All
patients underwent direct right heart catheterization for
assessment of pulmonary hemodynamics. A balloon catheter
was inserted through the femoral vein and advanced to the
capillary wedge position; no complication related to this pro-
cedure was observed. The following measurements were
recorded: heart rate, mean arterial pressure, mean pulmonary
artery pressure (mPA), central venous pressure, pulmonary
arterial wedge pressure (PAWP), and cardiac output. Cardiac
index was calculated as well as indexed pulmonary and sys-
temic vascular resistance (PVRI and SVRI) and intrapul-
monary shunt (Qs/Qt). All measurements were performed
with the patient breathing 100% oxygen. Pulmonary hyper-
tension was graded as mild/moderate (mPA between 20 and
25 mm Hg) and severe (mPA > 25 mm Hg). In patients with
pulmonary hypertension, hemodynamic measurements were
repeated after administration of inhaled nitric oxide (40 ppm)
(Politron NO and NO2; Dräger, Lubeck, Germany). The
radionuclide studies were performed by gated equilibrium
radionuclide ventriculography after a peripheral intravenous
injection of 750 MBq technetium 99m human serum albu-
min. A right ventricular ejection fraction of 45% was consid-
ered the lower normal limit. We compared data collected at
the time of evaluation from patients dying on the waiting list
(group I) with data on patients undergoing lung transplanta-
tion (group II) and patients still on the waiting list (group III).
A comparison was also made within group II between the
data collected at the time of evaluation and at the time of
transplantation to quantify the functional deterioration during
the waiting time. Hemodynamic measures were repeated
after induction of anesthesia, intubation, and double lung
mechanical ventilation to evaluate these parameters in the
absence of any emotional impact.
Statistical analyses among groups I, II, and III were per-
formed with the analysis of variance procedure (ANOVA);
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multiple comparisons among the three groups were per-
formed with the Tukey Studentized range test to evaluate the
specific significance of each group. The influence of each
variable on the outcome was evaluated with the Cox propor-
tional hazards model censoring patients at either the latest
day of follow-up alive on the waiting list or at the time of
transplantation. A χ2 test was used to analyze the echocardio-
graphic parameters. Repeated-measures analysis of variance
was used to study the response to inhaled nitric oxide in
group I, II and III patients with pulmonary hypertension.
Computations were performed with an SAS personal com-
puter (version 6.12; SAS Institute Inc, Cary, NC).
Results
Twenty-two of the 24 patients who underwent trans-
plantation are alive (mean follow-up, 16.8 months; 2-
year survival, 88%); infection was the cause of death in
the 2 patients not surviving the immediate postopera-
tive course. Three patients required cardiopulmonary
bypass during transplantation. The mean time on the
waiting list for groups I, II, and III was, respectively,
112 days (28-238 days), 121 days (1-281 days), and
178 days (45-328 days) (P = .09). All patients needed
continuous supplemental oxygen. Pseudomonas cepa-
cia colonization was equally present in the three
groups: 2 patients in group I (18%), 3 patients in group
II (13%), and 2 patients in group III (20%). No patient
in either group had clinically important liver dysfunc-
tion. The ANOVA procedure showed no differences for
age, weight, Schwachman score, spirometric data, 6-
minute walk test, and right ventricular ejection fraction
between groups I, II, and III (Table I) nor between
echocardiographic parameters (P = .5) (Table II). A sta-
tistically significant difference was found for
PaO2/FIO2, PaCO2, mPA, cardiac output, cardiac index,
PAWP, Qs/Qt, SVRI (Table III), and supplemental oxy-
gen requirement (P = .02); the Tukey test showed a sig-
nificant comparison at the .05 level between groups I
and II for all these parameters; differences between
groups I and III were present only for mPA, PaCO2, and
SVRI. No statistically significant difference was
observed between groups II and III. Mild to moderate
pulmonary hypertension was present in 1 patient (9%)
in group I, 10 (42%) in group II, and 2 (20%) in group
III; severe pulmonary hypertension was present in 10
(91%) patients in group I, 2 (8%) in group II, and 3
(30%) in group III (P = .02). All patients with pul-
monary hypertension were tested with inhaled nitric
oxide, and the percentage of responders and grade of
response did not differ among the three groups; the
degree of response to inhaled nitric oxide depended
only on the preadministration mPA: in fact, indepen-
dently from grouping, the condition of patients with
severe pulmonary hypertension (mean 35 ± 10 mm Hg)
improved considerably with inhaled nitric oxide (mean
28 ± 9 mm Hg) (P = .0006). The comparison within
Table I. Demographic and functional variables at the time of evaluation for patients dying while on the waiting list
(group I), reaching the time of transplantation (group II), and still on the waiting list (group III)
Group I Group II Group III P value
Age (y) 23 ± 7 20 ± 4 21 ± 3 .3
Weight (% of predicted) 82 ± 7 84 ± 7 84 ± 6 .2
FVC (%) 36 ± 7 37 ± 8 38 ± 6 .4
FEV1 18 ± 4 21 ± 6 21 ± 4 .4
RVEF (%) 46 ± 8 50 ± 5 51 ± 5 .2
6MWT (m) 295 ± 106 319 ± 82 338 ± 86 .5
Shwachman score 47 ± 2 46 ± 4 49 ± 6 .2
Waiting time (d) 112 (28-238) 121 (1-281) 178 (45-328) .09
FVC, Forced vital capacity; FEV1, forced expiratory volume in 1 second; RVEF, right ventricular ejection fraction; 6MWT, 6-minute walk test.
Table II. Echocardiographic study to assess morphology of the right ventricle at the time of evaluation for group I,
II and III patients (P = .5)
Hypertrophy + 
Normal Hypertrophy Dilatation dilatation
Group I 3 (27%) — 2 (18%) 6 (55%)
Group II 6 (25%) 2 (9%) 8 (33%) 8 (33%)
Group III 4 (40%) 2 (20%) 1 (10%) 3 (30%)
Total 13 4 11 17
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group II at the time of evaluation and the time of trans-
plantation showed a significant deterioration of pul-
monary hemodynamics during the waiting time, as well
as a deterioration in PaO2/FIO2 and PaCO2 (Table IV).
After induction of anesthesia, mPA did not show any
modification (32 ± 10 mm Hg vs 30 ± 6 mm Hg); other
hemodynamic parameters and oxygenation were rela-
tively modified by anesthesia and mechanical ventila-
tion. The Cox proportional hazards model demonstrat-
ed a trend toward an increased risk of death on the
waiting list for patients showing a deranged heart rate,
mPA, cardiac index, SVRI, PaO2/FIO2, Qs/Qt, and an
increased supplemental oxygen requirement (Table V).
Discussion
Potential recipients of lung transplants generally
exceed the supply of donors; for this reason a number
of patients will die on the waiting list. Previous reports
showed that patients with pulmonary fibrosis and CF
are at higher risk of death during the waiting time than
are other lung transplant candidates.7,8,10,12 Twenty-
four percent of our patients with CF did not live long
enough to undergo transplantation, a figure that is in
line with other reports.2-6 Death continues to be due in
most cases to progression of respiratory failure and
infectious exacerbations; cor pulmonale and pul-
monary hypertension are associated in the late phases
of the disease.11,13-15 Timing of referral is a crucial eth-
ical issue to reduce mortality on the waiting list and
improve results; however, actual predictors of death for
patients with CF are difficult to quantitate.3-5,16-21 They
should predict an 18-month survival and indicate the
possible beginning of the “transplant window.”
Table III. Blood gas analysis and hemodynamic variables in group I, II and III patients at the time of evaluation
Group I Group II Group III P value
HR (beats/min) 120 ± 21 105 ± 20 104 ± 13 .1
CO (L/min) 6.2 ± 1.3 4.9 ± 1 5.8 ± 1.5 .02
mAP (mm Hg) 77 ± 7 79 ± 8 80 ± 15 .85
mPA (mm Hg) 35 ± 12 22 ± 6 23 ± 6 .001
CVP (mm Hg) 2.6 ± 2 2 ± 1.5 3 ± 1.6 .6
PAWP (mm Hg) 6.6 ± 2.4 3.2 ± 2 5.1 ± 3.5 .007
CI (L · min–1 · m–2) 4.6 ± 1 3.5 ± 0.6 3.8 ± 0.7 .005
SVRI (dynes · s–5 · m–2) 1334 ± 240 1794 ± 371 1703 ± 436 .01
PVRI (dynes · s–5 · m–2) 492 ± 100 450 ± 139 392 ± 153 .2
PaO2/FIO2 191 ± 54 274 ± 63 258 ± 27 .002
PaCO2 (mm Hg) 65 ± 23 45 ± 5 50 ± 3 .002
Qs/Qt (%) 31 ± 7 23 ± 3 27 ± 4 .004
HR, Heart rate; CO, cardiac output; mAP, mean arterial pressure; mPA, mean pulmonary artery pressure; CI, cardiac index; SVRI, systemic vascular resistance
indexed; Qs/Qt, intrapulmonary shunt.
Table IV. Functional and hemodynamic variables in
patients (group II) reaching the time of transplantation;
data were collected at the time of evaluation (left) and
at the time of transplantation (right)
Evaluation Transplantation P value
FEV1 (L/s) 21 ± 6 20 ± 4.5 .4
Suppl. O2 (L/min) 1.7 ± 1 2.4 ± 1 .06
HR (beats/min) 105 ± 20 123 ± 17 .01
CO (L/min) 4.9 ± 1 5.4 ± 1.6 .3
mAP (mm Hg) 79 ± 8 86 ± 10 .01
mPA (mm Hg) 22 ± 6 32 ± 10 .005
CVP (mm Hg) 2 ± 1.5 4.8 ± 3.8 .1
PAWP (mm Hg) 3.2 ± 2 13 ± 6 .0001
CI (L · min–1 · m–2) 3.5 ± 0.6 3.8 ± 0.9 .2
SVRI (dynes · s–5 ·m–2) 1794 ± 371 1846 ± 538 .3
PVRI (dynes · s–5 ·m–2) 450 ± 139 421 ± 161 .7
PaO2/FIO2 274 ± 63 210 ± 28 .5
PaCO2 (mm Hg) 45 ± 5 52 ± 9 .8
Qs/Qt (%) 23 ± 3 38 ± 4 .004
FEV1, Forced expiratory volume in 1 second; Suppl. O2, supplemental oxygen
requirement; HR, heart rate; CO, cardiac output; mAP, mean arterial pressure;
mPA, mean pulmonary artery pressure; CVP, central venous pressure; PAWP,
pulmonary arterial wedge pressure; SVRI, systemic vascular resistance
indexed; PVRI, pulmonary vascular resistance indexed; Qs/Qt, intrapul-
monary shunt.
Table V. Results of Cox proportional hazards model
Variable Cox coefficient ± SE P value
HR 0.03 ± 0.01 .08
mPA 0.03 ± 0.01 .08
CI 0.4 ± 0.2 .09
SVRI 0.001 ± 0.0009 .05
PaO2/FIO2 0.01 ± 0.004 .01
Qs/Qt 0.08 ± 0.04 .04
Suppl. O2 1.14 ± 0.3 .001
HR, Heart rate; mPA, mean pulmonary artery pressure; CI, cardiac index;
SVRI, systemic vascular resistance indexed; Qs/Qt, intrapulmonary shunt;
Suppl. O2, supplemental oxygen requirement.
Pulmonary function tests are useful indicators: an
FEV1 less than 30% of predicted helps to identify a risk
of death of 50% within 2 years3.5 and it might be useful
to indicate when the “transplant window” should be
opened. Further deterioration of FEV1 is extremely
slow after reaching values lower than 20% of predicted,
as confirmed by our data (Table IV); on the other hand,
a sudden decrease may be associated with life-threat-
ening exacerbations and therefore may not follow the
predicted pattern. Hypercapnia presents a bizarre
course: all patients show moderate hypercapnia at the
time of evaluation, and this is considered an inclusion
criterion. PaCO2 may remain stable for a long time and
increase further only during infectious exacerbations or
increase slightly and then raise suddenly in the final
phase of the clinical course; it may also remain high
after infectious exacerbations or return to the previous
level. Noninvasive ventilation may contribute to ame-
lioration of tolerance of hypercapnia and prolong the
waiting time. For this reason, hypercapnia might
account for an advanced stage of the disease, but it is
unpredicatable at which phase of the “transplant win-
dow” each hypercapnic patient should be placed. Also,
hypoxia should be interpreted the same way. The 6-
minute walk test has been reported as a useful predic-
tive factor21: 400 m appears to be a reasonable cutoff
for listing patients for lung transplantation. However,
patients with CF show a high exercise tolerance if
compared with all the other groups, possibly because of
a blunted sensation of dyspnea related to their lifelong
battle with the disease. The 6-minute walk test results
may deteriorate dramatically after infectious exacerba-
tions. Most patients listed in our program showed a 6-
minute walk distance lower than 400 m, probably relat-
ed to a more advanced stage of the disease at the time
of referral, at least at the beginning of our experience.
However, there was no difference between patients
dying on the waiting list and those having a successful
transplantation; for this reason, we consider the 6-
minute walk test, along with other inclusion parame-
ters, as a good test to accept patients in the transplant
program, but it may be unreliable to define precisely
the evolution of the disease. No effect of nutritional sta-
tus on death on the waiting list was found,22 as con-
firmed by our data; however, 80% of predicted weight
for height is considered a cutoff to predict an increased
postoperative mortality.
CF appears to be a disease with many faces; it is a
debilitating disease due to malabsorption and metabol-
ic derangement; it is a septic disease; it shows an
obstructive pattern, but a restrictive deficit may accom-
pany the functional impairment. Sometimes it can be
all of the above at the same time, and sometimes one of
these aspects dominates and alters the clinical course
toward progressive decline and the possible death of
the patient. It is therefore not surprising that the quest
for reliable prognostic parameters, especially in com-
promised patients, is so difficult. No current test is uni-
versally applicable; in fact, spirometry and all the other
current parameters might well depict the status of one
patient while in other cases they could not justify the
rapid fatal outcome on the waiting list.
Hemodynamic data obtained in other patients with
parenchymal disorders are controversial with regard to
outcome.23-25 Our data suggest that patients with CF
show a deterioration of pulmonary hemodynamics in
the advanced phase of their disease, when it is more
likely for the many possible causes (parenchymal
destruction, obstructive disease, interstitial fibrosis,
left-to-right and right-to-left shunt, hyperdynamic
flow) to affect the pulmonary circulation. The occur-
rence and progression of hemodynamic impairment is
thus multifactorial and not surprisingly associated with
an increased risk of death on the waiting list. Increased
mPA, cardiac output, cardiac index, PAWP, and Qs/Qt
indicate a low life expectancy and an increased risk of
death within 6 to 8 months, and in this case patients
should be considered in the descending phase of the
“transplant window” and receive priority for organ
allocation. The hyperdynamic pattern recorded in
patients dying on the waiting list may recall sepsis and
could be attributed to infection; however, no clinical
data supported the existence of acute infectious com-
plications at the time of evaluation. This pattern was
also shown by most of our patients at the time of trans-
plantation, and these patients underwent successful
transplantation without any sign of infection during the
early postoperative course. We have also considered the
possibility that anxiety during cardiac catheterization at
the time of evaluation and immediately before trans-
plantation might have helped to modify pulmonary
hemodynamics; however, at the time of transplantation,
mPA and cardiac index were confirmed when measure-
ments were repeated after induction of anesthesia and
intubation. The Cox proportional hazards model con-
firmed a trend toward an increased risk of death on the
waiting list for most of these variables: however, the
multivariate analysis will be extremely useful when a
more consistent number of patients and events will be
available, to confirm these results and evaluate the
independent role of each variable. 
Echocardiographic evaluation is an extremely conve-
nient screening test14; however, it allows only estima-
tion of systolic pulmonary artery pressure; moderate
686 Venuta et al The Journal of Thoracic and
Cardiovascular Surgery
April 2000
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 4, Part 1
Venuta et al 687
pulmonary hypertension, especially in the presence of
obstructive pulmonary disease, may be difficult to
detect and rarely is able to correlate with mPA mea-
sured at right heart catheterization. The exact assess-
ment of pulmonary hemodynamics, necessary in our
opinion for all lung transplant candidates, should rely
on right heart catheterization,26 which should be elec-
tively performed at the time of evaluation. Right heart
catheterization is easy to perform, it shows a low rate of
complications, and it is well tolerated even in young
and pediatric patients.
The “transplant window” for patients with CF could
thus be redesigned (Fig 1). Standard criteria, such as
FEV1, hypoxia, hypercapnia, increased frequency and
severity of exacerbations, and increased frequency of
hospitalizations, are useful to include patients on the
waiting list. Further deterioration of PaO2, PaCO2, and
6-minute walk results confirms that each patient has
been correctly included in the initial phase of the pro-
gram waiting for the transplant window. Patients with
CF show a deterioration of pulmonary hemodynamics
in the advanced phase of their disease, and at that time
this deterioration predicts an increased risk of death.
These parameters contribute to identifying the individ-
ual to be in the second part of the transplant window,
and the short life expectancy could indicate a priority
for organ allocation.
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Discussion
Dr Robert Duane Davis (Durham, NC). Dr Venuta and his
colleagues have identified characteristics of those patients
with CF who are going to die before transplantation. What
are we going to do with the information? A 24% mortality for
patients on the waiting list is too high. Unfortunately, the
patients in the group that are described are dying within 4
months of listing. In the United States, currently we could not
do anything with this group of patients. The average waiting
times are approaching 2 to 3 years for patients requiring a
double lung transplant. Therefore, we have to get to them ear-
lier and then make decisions regarding their stability and
whether to proceed with transplantation. Even when it is pos-
sible to prioritize on the basis of severity of illness, some
patients referred that late in the disease process are not going
to survive long enough to undergo transplantation. How are
you going to use the information to provide feedback to your
pulmonologists and referring physicians so as to improve ear-
lier referral?
Additionally, you are demonstrating that the patients at risk
for early mortality have a hypermetabolic state with an
increased cardiac index and a decreased systemic vascular
resistance. However, pulmonary vascular resistance was only
mildly elevated, and the increase was not statistically signifi-
cant. This raises a couple of questions. Can you do something
noninvasively, such as a metabolic heart study, to differenti-
ate the patients either at listing or later? Second, is this just
the nature of the infectious aspects of the disease? Are the
patients who died earlier more likely to have Burkholderia
cepacia or panresistant Pseudomonas? Did they have a
greater infectious burden?
How are you going to stratify your patients? Obviously,
donor lungs are a limited resource, and you are going to try
to use them so as to lessen your overall mortality. How do
you triage patients as they enter the evaluation phase and are
monitored while waiting? I assume that you do not repeat
invasive studies of pulmonary hemodynamics.
This paper reiterates our biggest problem, the limited num-
ber of donor organs. We need alternative ways to treat
patients when they get sick so that they can live longer, and
then we need alternative ways to get more organs for these
patients or alternative therapies.
Dr Venuta. Dr Davis, thank you for your comments and
questions. I will try to answer them point by point.
The present series represents our initial experience in coop-
eration with the CF group at our institution. At the beginning
we were able to enroll in our program only a small number of
patients, and many of them were at an advanced phase of
their disease. As a result, most of the patients either under-
went transplantation or died within 6 months. We have shared
this information with our referring physicians to persuade
them to consider lung transplant candidates at an earlier
stage; for this reason, we are now enrolling patients in better
condition. However, even if patients with CF are considered
earlier for lung transplantation, we continue to take their
hemodynamic pattern extremely seriously. In fact, not more
than a few weeks ago we lost a young patient after only 3
months on the waiting list. He was not extremely hypercap-
nic, the FEV1 was around 25%, but his mPA was above 40
mm Hg, confirming the data that we just reported.
Concerning the possible role of sepsis, we have to remem-
ber that these patients have chronic infections, and the low
systemic vascular resistance may reflect this aspect. We agree
that the metabolic state could and should be investigated
more extensively. A precise multivariate analysis, which
could not be performed in this small series, will certainly add
more information in the future. In this series, no patient had
an active infection either at the time of evaluation or at the
time of transplantation. There was no difference among the
three groups in terms of Pseudomonas cepacia colonization.
Triage is an important point. The waiting time is and will
be the most important parameter to indicate priority on the
waiting list. However, competition for a graft exists among
CF patients and also with patients with other diseases, such
as pulmonary fibrosis, who are at an increased risk of death
during the waiting time. Also, a small number of patients
eventually are intubated and wait for the transplant in the
intensive care unit. For all these reasons, priority may be indi-
cated according to different parameters; if all the patients on
the list and with the same blood group and adequate size are
in stable condition, we would probably favor CF patients with
the most deranged hemodynamic pattern.
Dr Thomas M. Egan (Chapel Hill, NC). Your groups were
defined according to outcome, and then you used data
acquired at the time of evaluation to do your study. Did you
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ever update this information in any of the patients? Given
your results, that is, that pulmonary hypertension is associat-
ed with a poorer outcome, do you plan to update this infor-
mation? It would seem that it might be reasonable to perform
right heart catheterizations every 3 or 6 months in some of
these patients if you can identify the ones who are sicker. 
I would also like to raise an issue to which Dr Davis allud-
ed: In the United States if a patient comes to the hospital and
dies within 4 months, we cannot do anything about that.
Under the current algorithm, that is true. However, the
Department of Health and Human Services has instructed
UNOS to do something about that, and I am optimistic that
maybe we can do something about that. It will be information
such as you have provided that will help us sort out who is the
sickest and who should be given an opportunity for trans-
plantation over other patients. Frankly, if the patient’s condi-
tion is far advanced when we first see him or her, we worry
about why the patient is such a late referral. In some
instances, the patient really did not want to receive a trans-
plant at all and is merely trying to please parents or family
members. 
Dr Venuta. Thank you, Dr Egan, for your comments and
questions.
All of our patients receive echocardiography in adjunct to
right heart catheterization at the time of evaluation; this is a
cost-effective investigation, and it may be useful in many
patients. However, data obtained with the echocardiogram are
often different from those obtained with invasive means. We
usually update our data with echocardiography every 3
months. We plan to repeat right heart catheterization every
year if the patients wait for a long time for transplantation.
Since our waiting list is slowly growing, we assume that it
will be more common in the future.
Dr Joel D. Cooper (St Louis, Mo). Your group from Rome
has been making major contributions to all of the thoracic
meetings and I very much enjoyed your presentation. 
I want to expand on a point that Dr Egan mentioned. You
have used your data to retroactively look at the patient’s orig-
inal status. Obviously, doing this prospectively will be of
benefit. 
I have two questions. If you had these patients exercise at
the outset, could you distinguish between those who had
more reserve and those who did not? We have never done
that, either in transplant or volume reduction. We measure a
static pulmonary artery pressure. We know that when those
patients have trouble postoperatively, their pulmonary pres-
sures can sometimes become very high. So I wonder whether
a protocol is in order. When you do the right heart catheteri-
zations or studies, do you think having the patients exercise
might help you differentiate between those who are at greater
risk of having pulmonary hypertensive problems and those
who are not? 
Second, was there any particular pulmonary artery pressure
measurement above which two thirds had problems and
below which two thirds did not? Was any particular range
indicative, other than just the mean of the group? 
Dr Venuta. Dr Cooper, I wish to thank you for your com-
ments and suggestions. It will be interesting to evaluate pul-
monary hemodynamics during exercise. We are performing a
stress test with dobutamine, but the preliminary results are not
yet available. Concerning your second question, according to
the World Health Organization, pulmonary hypertension is
considered severe when the mPA is above 25 mm Hg. In
group I we had only 1 patient with moderate pulmonary
hypertension (mPA < 25 mm Hg) and the other 10 patients
showed mPAs above 30 mm Hg. For this reason, 30 mm Hg is
a good cutoff point, in particular if we consider that only 2 and
3 patients, respectively, in groups II and III had such mPAs.
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